Citations (180)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (36)
Parvej Khan, Shubhashree Venkatesh, Rizwana Parveen, Pinki Mishra, Seema Jain & Nidhi Agarwal. (2023) Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Expert Opinion on Pharmacotherapy 0:0, pages 1-12.
Read now
Read now
Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Shinya Nishio, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane, Shigenori Ando & Emiko Tsugami. (2019) Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 12, pages 1783-1794.
Read now
Read now
Katherine Merton, Michael J. Davies, Ujjwala Vijapurkar, Doreen Inman & Gary Meininger. (2018) Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. Current Medical Research and Opinion 34:2, pages 313-318.
Read now
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis & Vasilios G. Athyros. (2017) The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology 10:11, pages 1251-1261.
Read now
Read now
Michael J Davies, Katherine W Merton, Ujjwala Vijapurkar, Dainius A Balis & Mehul Desai. (2017) Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Metabolic Syndrome and Obesity 10, pages 47-55.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2017) Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Expert Review of Clinical Pharmacology 10:6, pages 633-647.
Read now
Read now
Rong Qiu, Dainius Balis, John Xie, Michael J. Davies, Mehul Desai & Gary Meininger. (2017) Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion 33:3, pages 553-562.
Read now
Read now
Thomas C. Blevins & Azeez Farooki. (2017) Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine 129:1, pages 159-168.
Read now
Read now
Guntram Schernthaner, Fernando J. Lavalle-González, Jaime A. Davidson, Holly Jodon, Ujjwala Vijapurkar, Rong Qiu & William Canovatchel. (2016) Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgraduate Medicine 128:8, pages 725-730.
Read now
Read now
Maria Alba, John Xie, Albert Fung & Mehul Desai. (2016) The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 32:8, pages 1375-1385.
Read now
Read now
Karen S.L. Lam, Chun Chung Chow, Kathryn C.B. Tan, Ronald C.W. Ma, Alice P.S. Kong, Peter C.Y. Tong, Man Wo Tsang, Tak Mao Chan, Sydney C.W. Tang, Ka Kui Lee, Wing Yee So & Brian Tomlinson. (2016) Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Current Medical Research and Opinion 32:6, pages 1097-1108.
Read now
Read now
Sarah Thayer, Wing Chow, Stephanie Korrer & Richard Aguilar. (2016) Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Current Medical Research and Opinion 32:6, pages 1087-1096.
Read now
Read now
Lawrence Blonde, Kaj Stenlöf, Albert Fung, John Xie, William Canovatchel & Gary Meininger. (2016) Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine 128:4, pages 371-380.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
Fernando J. Lavalle-González, Freddy G. Eliaschewitz, Sonia Cerdas, Maria Del Pilar Chacon, Cindy Tong & Maria Alba. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current Medical Research and Opinion 32:3, pages 427-439.
Read now
Read now
Rizwana Parveen, Nidhi Bharal Agarwal, Neelam Kaushal, Ghanshyam Mali & Sheikh Raisuddin. (2016) Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opinion on Pharmacotherapy 17:1, pages 105-115.
Read now
Read now
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
Read now
Jochen Seufert. (2015) SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity 8, pages 543-554.
Read now
Read now
Molly G. Minze, Robin L. Koffarnus, Trista A. Bailey, Sandy Diec & Krystal L. Edwards. (2015) Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy. Expert Review of Endocrinology & Metabolism 10:6, pages 645-661.
Read now
Read now
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel & Gary Meininger. (2015) Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion 31:11, pages 1993-2000.
Read now
Read now
Robert M. Guthrie. (2015) Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgraduate Medicine 127:5, pages 463-479.
Read now
Read now
Jennifer N. Clements, Heather P. Whitley, Jennifer J. D’Souza, Benjamin Gross, Rick Hess, Sara Reece, Chad Gentry & Kayce Shealy. (2015) Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Current Medical Research and Opinion 31:9, pages 1733-1741.
Read now
Read now
L.M. Meckley, G. Miyasato, F. Kokkotos, J. Bumbaugh & R.A. Bailey. (2015) An observational study of glycemic control in canagliflozin treated patients. Current Medical Research and Opinion 31:8, pages 1479-1486.
Read now
Read now
Erin K. Buysman, Wing Chow, Henry J. Henk & Marcia F.T. Rupnow. (2015) Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Current Medical Research and Opinion 31:1, pages 137-143.
Read now
Read now
Michael A Nauck. (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 8, pages 1380-1380.
Read now
Read now
Rosemarie Lajara. (2014) The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 15:17, pages 2565-2585.
Read now
Read now
Brian K Irons & Molly G Minze. (2014) Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes, Metabolic Syndrome and Obesity 7, pages 15-24.
Read now
Read now
Jaime A. Davidson & Louis Kuritzky. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine 126:6, pages 33-48.
Read now
Read now
Matthew R. Weir, Irina Kline, John Xie, Robert Edwards & Keith Usiskin. (2014) Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Current Medical Research and Opinion 30:9, pages 1759-1768.
Read now
Read now
Stephen Brunton & Timothy S. Reid. (2014) Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice 42:3, pages 96-108.
Read now
Read now
Paul Nyirjesy, Jack D. Sobel, Albert Fung, Cristiana Mayer, George Capuano, Kirk Ways & Keith Usiskin. (2014) Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion 30:6, pages 1109-1119.
Read now
Read now
Keith Usiskin, Irina Kline, Albert Fung, Cristiana Mayer & Gary Meininger. (2014) Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results. Postgraduate Medicine 126:3, pages 16-34.
Read now
Read now
Shana Traina, Robert Guthrie & April Slee. (2014) The Impact of Weight Loss on Weight-related Quality of Life and Health Satisfaction: Results From a Trial Comparing Canagliflozin With Sitagliptin in Triple Therapy Among People With Type 2 Diabetes. Postgraduate Medicine 126:3, pages 7-15.
Read now
Read now
Kaj Stenlöf, William T. Cefalu, Kyoung-Ah Kim, Esteban Jodar, Maria Alba, Robert Edwards, Cindy Tong, William Canovatchel & Gary Meininger. (2014) Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Current Medical Research and Opinion 30:2, pages 163-175.
Read now
Read now
Lindsay E. Nicolle, George Capuano, Albert Fung & Keith Usiskin. (2014) Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. Postgraduate Medicine 126:1, pages 7-17.
Read now
Read now
Eric Dietrich, Jason Powell & James R Taylor. (2013) Canagliflozin: a novel treatment option for type 2 diabetes. Drug Design, Development and Therapy 7, pages 1399-1408.
Read now
Read now
Articles from other publishers (144)
Hong-Da Zhang, Lei Ding, Li-Jie Mi, Ai-Kai Zhang, Kuo Zhang, Zi-Han Jiang, Feng-Yuan Yu, Xin-Xin Yan, Yu-Jing Shen & Min Tang. (2023) Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. European Journal of Preventive Cardiology.
Crossref
Crossref
Chun Xing Li, Li Yan Liu, Chen Xiao Zhang, Xu Hua Geng, Si Meng Gu, Yu Qiao Wang, Hua Liu, Qing Xie & Shuo Liang. (2023) Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology 14.
Crossref
Crossref
Louise E. Bechmann, Frida Emanuelsson, Børge G. Nordestgaard & Marianne Benn. (2023) SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis, pages 117236.
Crossref
Crossref
Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song & Deqiu Zhu. (2023) Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Frontiers in Endocrinology 14.
Crossref
Crossref
Shiwen Yang, Ying Liu, Shengzhao Zhang, Fengbo Wu, Dan Liu, Qingfang Wu, Hanrui Zheng, Ping Fan & Na Su. (2023) Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Pharmacology 14.
Crossref
Crossref
Mingdi Liu, Jichao Liu, Qiuhong Wang, Ping Song, Haichao Li, Songgu Wu & Junbo Gong. (2023) Quantitative analysis of low content polymorphic impurities in canagliflozin tablets by PXRD, NIR, ATR-FITR and Raman solid-state analysis techniques combined with stoichiometry. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 293, pages 122458.
Crossref
Crossref
Runzhou Pan, Yan Zhang, Rongrong Wang, Yao Xu, Hong Ji & Yongcai Zhao. (2022) Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLOS ONE 17:12, pages e0279889.
Crossref
Crossref
Nicolas Loiseau, Paul Trichelair, Maxime He, Mathieu Andreux, Mikhail Zaslavskiy, Gilles Wainrib & Michael G. B. Blum. (2022) External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Bo Xu, Shaoqian Li, Bo Kang & Jiecan Zhou. (2022) The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular Diabetology 21:1.
Crossref
Crossref
Yao H. Teo, Alys Z.Q. Chia, Yao N. Teo, Elliot Y. Chong, Nicholas L. Syn, Jia Y.A. Cheong, How T. Ong, Caitlin F. Wee, Adriel Z.H. Ting, Joshua T.A. Tan, Tony Y.W. Li, William K.F. Kong, Chi-Hang Lee, Mark Y.-Y. Chan, Raymond C.C. Wong, Tiong-Cheng Yeo, Ping Chai & Ching-Hui Sia. (2022) The impact of sodium–glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials. Journal of Hypertension 40:12, pages 2353-2372.
Crossref
Crossref
Ahasanul Hasan, Farzana Zerin, Sreelakshmi N. Menon, Md. Ashraful Alam & Raquibul Hasan. (2022) Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure. Journal of Pharmacological Sciences 150:4, pages 211-222.
Crossref
Crossref
Hang-Long Li, Yi-Kei Tse, Chanchal Chandramouli, Nicole Wing-Lam Hon, Ching-Lung Cheung, Lok-Yee Lam, Meizhen Wu, Jia-Yi Huang, Si-Yeung Yu, Ka-Lam Leung, Yue Fei, Qi Feng, Qingwen Ren, Bernard M Y Cheung, Hung-Fat Tse, Subodh Verma, Carolyn S P Lam & Kai-Hang Yiu. (2022) Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. The Journal of Clinical Endocrinology & Metabolism 107:12, pages 3442-3451.
Crossref
Crossref
Xi Rong, Yawen Zhu, Bo Wen, Kai Liu, Xinran Li, Qiling Gou & Xiaoping Chen. (2022) Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Sumanth KHAKDE, Hafsa JAWAID, Farah YASMIN, Mashal BINTE ALI & Abdur REHMAN. (2022) Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinology 47:3.
Crossref
Crossref
Henri Gouraud, Joshua D Wallach, Rémy Boussageon, Joseph S Ross & Florian Naudet. (2022) Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis. BMJ Medicine 1:1, pages e000154.
Crossref
Crossref
Yao Neng Teo, Adriel Z. H. Ting, Yao Hao Teo, Elliot Yeung Chong, Joshua Teik Ann Tan, Nicholas L. Syn, Alys Z. Q. Chia, How Ting Ong, Alex Jia Yang Cheong, Tony Yi-Wei Li, Kian Keong Poh, Tiong Cheng Yeo, Mark Yan-Yee Chan, Raymond C. C. Wong, Ping Chai & Ching-Hui Sia. (2022) Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. American Journal of Cardiovascular Drugs 22:3, pages 299-323.
Crossref
Crossref
Lana C. Pinto, Dimitris V. Rados, Luciana R. Remonti, Marina V. Viana, Cristiane B. Leitão & Jorge L. Gross. (2022) Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Archives of Endocrinology and Metabolism 66:1, pages 68-76.
Crossref
Crossref
Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2022) Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022, pages 1-17.
Crossref
Crossref
Yao Wang, Xian Shao & Zewen Liu. (2022) Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly <i>versus</i> non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocrine Journal 69:6, pages 669-679.
Crossref
Crossref
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y. Chan, Tiong-Cheng Yeo, Raymond C. C. Wong, Ping Chai & Ching-Hui Sia. (2022) Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Therapeutic Advances in Chronic Disease 13, pages 204062232210835.
Crossref
Crossref
Alex Jia Yang Cheong, Yao Neng Teo, Yao Hao Teo, Nicholas L. Syn, How Ting Ong, Adriel Z. H. Ting, Alys Z. Q. Chia, Elliot Yeung Chong, Mark Y. Chan, Chi‐Hang Lee, Amanda Yuan Ling Lim, William K. F. Kong, Raymond C. C. Wong, Ping Chai & Ching‐Hui Sia. (2021) SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials. Obesity 30:1, pages 117-128.
Crossref
Crossref
Edoardo Mannucci. (2021) Which antidiabetic drug indications are recommended for geriatric DM patients?. Journal of Gerontology and Geriatrics 69:4, pages 276-281.
Crossref
Crossref
Denis A. Lebedev, Elena A. Lyasnikova, Elena Yu. Vasilyeva, Nikolai P. Likhonosov, Maria Yu. Sitnikova & Alina Yu. Babenko. (2021) Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research 2021, pages 1-8.
Crossref
Crossref
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A. Katus, Morten Grundtvig, John G. F. Cleland, Andrew L. Clark, Hanna Fröhlich & Lutz Frankenstein. (2020) Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews 26:6, pages 1421-1435.
Crossref
Crossref
Arjun K. Pandey, Iva Okaj, Hargun Kaur, Emilie P. Belley‐Cote, Jia Wang, Alireza Oraii, Alexander P. Benz, Linda S. B. Johnson, Jack Young, Jorge A. Wong, Subodh Verma, David Conen, Hertzel Gerstein, Jeff S. Healey & William F. McIntyre. (2021) Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association 10:17.
Crossref
Crossref
Manuel A. Gargallo-Fernández, Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Miguel Brito-Sanfiel, Jaime Wong-Cruz & Juan J. Gorgojo-Martínez. (2021) Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study. Diabetology 2:3, pages 165-175.
Crossref
Crossref
Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho & Adelino Leite‐Moreira. (2020) Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials. Diabetes/Metabolism Research and Reviews 37:6.
Crossref
Crossref
Lei Tian, Yuzi Cai, Huijuan Zheng, Sinan Ai, Mengqi Zhou, Qian Luo, Jingyi Tang, Weijing Liu & Yaoxian Wang. (2021) Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology 12.
Crossref
Crossref
Daobo Li, Yingying Liu, Tesfaldet Habtemariam Hidru, Xiaolei Yang, Yunsong Wang, Cheng Chen, Ka Hou Christien Li, Yuqi Tang, Yushan Wei, Gary Tse & Yunlong Xia. (2021) Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials. Frontiers in Endocrinology 12.
Crossref
Crossref
Mao-bing Chen, Hua Wang, Wei-yan Cui, Hua-lan Xu & Qi-han Zheng. (2021) Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus. Medicine 100:6, pages e24593.
Crossref
Crossref
Mao-Bing Chen, Hua Wang, Qi-Han Zheng, Hua-Lan Xu & Wei-Yan Cui. (2021) Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus. Medicine 100:1, pages e24101.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis & Pantelis Sarafidis. (2020) The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry 27:39, pages 6682-6702.
Crossref
Crossref
Adriana Sánchez-García, Mario Simental-Mendía, Juan Manuel Millán-Alanís & Luis E. Simental-Mendía. (2020) Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacological Research 160, pages 105068.
Crossref
Crossref
Xi Rong, Xinran Li, Qiling Gou, Kai Liu & Xiaoping Chen. (2020) Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diabetes and Vascular Disease Research 17:5, pages 147916412095362.
Crossref
Crossref
Kazuomi Kario, Keith C. Ferdinand & James H. O'Keefe. (2020) Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress in Cardiovascular Diseases 63:3, pages 249-262.
Crossref
Crossref
Mengdie Hu, Xiaoling Cai, Wenjia Yang, Simin Zhang, Lin Nie & Linong Ji. (2020) Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis. Journal of the American Heart Association 9:7.
Crossref
Crossref
Salvatore Carbone & Dave L. Dixon. (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A. Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Jennifer B. Rose, Delna Sorabji & Harpreet S. Bajaj. (2019) CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice. Canadian Journal of Diabetes 43:7, pages 464-471.
Crossref
Crossref
Konstantinos Imprialos, Konstantinos Stavropoulos & Vasilios Papademetriou. (2019) Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics 15:4, pages 519-530.
Crossref
Crossref
Kathryn S Taylor, Julie Mclellan, Jan Y Verbakel, Jeffrey K Aronson, Daniel S Lasserson, Nicola Pidduck, Nia Roberts, Susannah Fleming, Christopher A O'Callaghan, Clare R Bankhead, Amitava Banerjee, FD Richard Hobbs & Rafael Perera. (2019) Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. BMJ Open 9:9, pages e030596.
Crossref
Crossref
Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci & Matteo Monami. (2019) Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 21:8, pages 1871-1877.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis & Pantelis Sarafidis. (2019) The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry 11:11, pages 1285-1303.
Crossref
Crossref
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria-Inti Metzendorf, Bernd Richter & Bianca Hemmingsen. (2019) Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Derek J. Nunez, Myriam Alexander, Laura Yerges-Armstrong, Gurparkash Singh, Geert Byttebier, Elisa Fabbrini, Dawn Waterworth, Gary Meininger, Nicholas Galwey, Lars Wallentin, Harvey D. White, Bart Vannieuwenhuyse, William Alazawi, Stuart Kendrick, Naveed Sattar & Ele Ferrannini. (2019) Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. American Journal of Physiology-Gastrointestinal and Liver Physiology 316:3, pages G372-G386.
Crossref
Crossref
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A. Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D. Culham, Jennifer B. Rose, Wally Rapattoni & Harpreet S. Bajaj. (2018) CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, Obesity and Metabolism 21:3, pages 691-699.
Crossref
Crossref
Kristin K. Clemens, Niamh O’Regan & Jinnie J. Rhee. (2019) Diabetes Management in Older Adults With Chronic Kidney Disease. Current Diabetes Reports 19:3.
Crossref
Crossref
Tuba M. Ansary, Daisuke Nakano & Akira Nishiyama. (2019) Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. International Journal of Molecular Sciences 20:3, pages 629.
Crossref
Crossref
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho & Andrei C. Sposito. (2019) Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista da Associação Médica Brasileira 65:1, pages 70-86.
Crossref
Crossref
William V Tamborlane, David Polidori, Domenick Argenti & Nicholas A Di Prospero. (2018) Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 19:4, pages 649-655.
Crossref
Crossref
Samuel Seidu, Setor K. Kunutsor, Xavier Cos, Syed Gillani & Kamlesh Khunti. (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes 12:3, pages 265-283.
Crossref
Crossref
Lin Zhang, Mei Zhang, Qingguo Lv & Nanwei Tong. (2018) Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 140, pages 295-303.
Crossref
Crossref
YL Shao, KH Yee, SK, Koh, YF Wong, LY Yeoh, S Low & CF Sum. (2018) Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting. Singapore Medical Journal 59:5, pages 251-256.
Crossref
Crossref
Graydon S. Meneilly, Aileen Knip, David B. Miller, Diana Sherifali, Daniel Tessier & Afshan Zahedi. (2018) Diabetes in Older People. Canadian Journal of Diabetes 42, pages S283-S295.
Crossref
Crossref
R. Gómez-Huelgas, F. Gómez Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig Domingo, J.J. Mediavilla Bravo, C. Miranda & J. Ena. (2018) Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. Revista Española de Geriatría y Gerontología 53:2, pages 89-99.
Crossref
Crossref
R. Gómez-Huelgas, F. Gómez Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig Domingo, J.J. Mediavilla Bravo, C. Miranda & J. Ena. (2018) Treatment of type 2 diabetes mellitus in elderly patients. Revista Clínica Española (English Edition) 218:2, pages 74-88.
Crossref
Crossref
R. Gómez-Huelgas, F. Gómez Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig Domingo, J.J. Mediavilla Bravo, C. Miranda & J. Ena. (2018) Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. Revista Clínica Española 218:2, pages 74-88.
Crossref
Crossref
G. Sesti, R. Antonelli Incalzi, E. Bonora, A. Consoli, A. Giaccari, S. Maggi, G. Paolisso, F. Purrello, G. Vendemiale & N. Ferrara. (2018) Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases 28:3, pages 206-218.
Crossref
Crossref
Mohammed Mohsen SafhiTarique AnwerGyas KhanRahimullah SiddiquiSivagurunathan Moni SivakumarMohammad Firoz Alam. (2018)
The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers
via
modulation of inflammatory cytokines in type 2 diabetic rats
. The Korean Journal of Physiology & Pharmacology 22:5, pages 493.
Crossref
Crossref
Takuo Yoshimoto, Takayuki Furuki, Hiroyuki Kobori, Masaaki Miyakawa, Hitomi Imachi, Koji Murao & Akira Nishiyama. (2023) Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 Diabetes. Journal of Investigative Medicine 65:7, pages 1057-1061.
Crossref
Crossref
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim, Gill Hamilton & Sami T. Azar. (2017) Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). International Journal of Clinical Practice 71:10, pages e12991.
Crossref
Crossref
Sarah Thayer, Richard Aguilar, Stephanie Korrer & Wing Chow. (2017) HbA 1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans. Clinical Therapeutics 39:10, pages 2061-2072.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Daniel Wolverton & Melissa M. Blair. (2017) Fracture risk associated with common medications used in treating type 2 diabetes mellitus. American Journal of Health-System Pharmacy 74:15, pages 1143-1151.
Crossref
Crossref
James L. JanuzziJr.Jr., Javed Butler, Petr Jarolim, Naveed Sattar, Ujjwala Vijapurkar, Mehul Desai & Michael J. Davies. (2017) Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. Journal of the American College of Cardiology 70:6, pages 704-712.
Crossref
Crossref
Lubin Xu, Yang Li, Jiaxin Lang, Peng Xia, Xinyu Zhao, Li Wang, Yang Yu & Limeng Chen. (2017) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ 5, pages e3405.
Crossref
Crossref
June Felice Johnson, Rahul Parsa & Robert A. Bailey. (2017) Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA 1c and Age. Clinical Therapeutics 39:6, pages 1123-1131.
Crossref
Crossref
Eirini Lioudaki, Emmanouil S. Androulakis, Martin Whyte, Konstantinos G. Stylianou, Eugenios K. Daphnis & Emmanouil S. Ganotakis. (2017) The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. Cardiovascular Drugs and Therapy 31:2, pages 215-225.
Crossref
Crossref
Nina A. Petunina, Anna L. Terekhova & Ekaterina V. Goncharova. (2016) Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor. Diabetes mellitus 19:6, pages 511-517.
Crossref
Crossref
Heidi Storgaard, Lise L. Gluud, Cathy Bennett, Magnus F. Grøndahl, Mikkel B. Christensen, Filip K. Knop & Tina Vilsbøll. (2016) Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLOS ONE 11:11, pages e0166125.
Crossref
Crossref
Belén Dalama & Jordi Mesa. (2016) Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. Revista Española de Cardiología 69:11, pages 1088-1097.
Crossref
Crossref
Belén Dalama & Jordi Mesa. (2016) New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border. Revista Española de Cardiología (English Edition) 69:11, pages 1088-1097.
Crossref
Crossref
Gabriel Cuatrecasas & Fernando Goñi-Goicoechea. (2016) Perfil clínico de los pacientes con diabetes mellitus tipo 2 tratados con inhibidores del cotransportador sodio-glucosa tipo 2 y experiencia clínica real en España. Medicina Clínica 147, pages 30-34.
Crossref
Crossref
Mathew John, Sonia Cerdas, Rafael Violante, Chaicharn Deerochanawong, Mohamed Hassanein, April Slee, William Canovatchel & Gill Hamilton. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice 70:9, pages 775-785.
Crossref
Crossref
Robert A. Bailey, Phil Schwab, Yihua Xu, Margaret Pasquale & Andrew Renda. (2016) Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice. Clinical Therapeutics 38:9, pages 2046-2057.e2.
Crossref
Crossref
H. W. Rodbard, J. Seufert, N. Aggarwal, A. Cao, A. Fung, M. Pfeifer & M. Alba. (2016) Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes, Obesity and Metabolism 18:8, pages 812-819.
Crossref
Crossref
Richard E. Gilbert, Matthew R. Weir, Paola Fioretto, Gordon Law, Mehul Desai, Irina Kline, Wayne Shaw & Gary Meininger. (2016) Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes 40:3, pages 247-257.
Crossref
Crossref
Alena Adamíková. (2016) Canagliflozin-inhibitor SGLT2 in diabetes mellitus therapy. Interní medicína pro praxi 18:2, pages 103-106.
Crossref
Crossref
Julio Rosenstock, Leonard Chuck, Manuel González-Ortiz, Kate Merton, Jagriti Craig, George Capuano & Rong Qiu. (2016) Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. Diabetes Care 39:3, pages 353-362.
Crossref
Crossref
Alan J. Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Wayne Shaw, Mehul Desai & Gary Meininger. (2016) Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society 64:3, pages 543-552.
Crossref
Crossref
S. P. Rajeev, D. J. Cuthbertson & J. P. H. Wilding. (2016) Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes, Obesity and Metabolism 18:2, pages 125-134.
Crossref
Crossref
L.A. Leiter, T. Forst, D. Polidori, D.A. Balis, J. Xie & S. Sha. (2016) Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes & Metabolism 42:1, pages 25-32.
Crossref
Crossref
G. Fulcher, D. R. Matthews, V. Perkovic, D. de Zeeuw, K. W. Mahaffey, C. Mathieu, V. Woo, C. Wysham, G. Capuano, M. Desai, W. Shaw, F. Vercruysse, G. Meininger & B. Neal. (2016) Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 18:1, pages 82-91.
Crossref
Crossref
Francesc Formiga, Ricardo Gómez-Huelgas & Leocadio Rodríguez Mañas. (2016) Características diferenciales de la diabetes mellitus tipo 2 en el paciente anciano. Papel de los inhibidores de la dipeptidil peptidasa 4. Revista Española de Geriatría y Gerontología 51:1, pages 44-51.
Crossref
Crossref
Grabner Michael, Peng Xiaomei, Caroline Geremakis & Jay Bae. (2015) Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Journal of Managed Care & Specialty Pharmacy 21:12, pages 1204-1212.
Crossref
Crossref
Cheryl Neslusan, Anna Teschemaker, Pierre Johansen, Michael Willis, Atanacio Valencia-Mendoza & Andrea Puig. (2015) Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues 8, pages 8-19.
Crossref
Crossref
Badieh Jafari & Mary E. Britton. (2015) Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention. Journal of Pharmacy Practice and Research 45:4, pages 459-469.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
Konstantinos P. Imprialos, Pantelis A. Sarafidis & Asterios I. Karagiannis. (2015) Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension 33:11, pages 2185-2197.
Crossref
Crossref
Ting Yang, Min Lu, Lingyue Ma, Ying Zhou & Yimin Cui. (2015) Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. European Journal of Clinical Pharmacology 71:11, pages 1325-1332.
Crossref
Crossref
Yehuda Handelsman. (2015) Potential Place of SGLT2 Inhibitors in Treatment Paradigms for type 2 Diabetes Mellitus. Endocrine Practice 21:9, pages 1054-1065.
Crossref
Crossref
Ngozi Erondu, Mehul Desai, Kirk Ways & Gary Meininger. (2015) Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 38:9, pages 1680-1686.
Crossref
Crossref
Greg Fulcher, David R. Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Robert Weiss, Julio Rosenstock, George Capuano, Mehul Desai, Wayne Shaw, Frank Vercruysse, Gary Meininger & Bruce Neal. (2015) Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy 6:3, pages 289-302.
Crossref
Crossref
Xia Chen, Pei Hu, Nicole Vaccaro, David Polidori, Christopher R. Curtin, Hans Stieltjes, Sue Sha, Sveta Weiner & Damayanthi Devineni. (2015) Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Clinical Therapeutics 37:7, pages 1483-1492.e1.
Crossref
Crossref
Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Hans Stieltjes, Jay Ariyawansa, Nicholas A. Di Prospero & Paul Rothenberg. (2015) Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clinical Pharmacology in Drug Development 4:4, pages 279-286.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref
John P.H. Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy Tong, Jacqueline Yee & Gary Meininger. (2015) Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and its Complications 29:3, pages 438-444.
Crossref
Crossref
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2015) Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care 38:3, pages 403-411.
Crossref
Crossref
Lawrence A. Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A. Balis, Dawn Millington, Frank Vercruysse, William Canovatchel & Gary Meininger. (2015) Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care 38:3, pages 355-364.
Crossref
Crossref
Aris Liakos, Thomas Karagiannis, Eleni Bekiari & Apostolos Tsapas. (2015) Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. Diabetes Management 5:2, pages 119-125.
Crossref
Crossref
B. Bode, K. Stenlöf, S. Harris, D. Sullivan, A. Fung, K. Usiskin & G. Meininger. (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes, Obesity and Metabolism 17:3, pages 294-303.
Crossref
Crossref
Damayanthi Devineni, Christopher R. Curtin, Thomas C. Marbury, William Smith, Nicole Vaccaro, David Wexler, An Vandebosch, Sarah Rusch, Hans Stieltjes & Ewa Wajs. (2015) Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. Clinical Therapeutics 37:3, pages 610-628.e4.
Crossref
Crossref
Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Donna Skee, Ewa Wajs, Rao N. V. S. Mamidi, Hong Tian, An Vandebosch, Shean-Sheng Wang, Tom Verhaeghe, Hans Stieltjes & Keith Usiskin. (2015) Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Clinical Pharmacology in Drug Development 4:3, pages 226-236.
Crossref
Crossref
S. Sha, D. Polidori, K. Farrell, A. Ghosh, J. Natarajan, N. Vaccaro, J. Pinheiro, P. Rothenberg & L. Plum‐Mörschel. (2015) Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study. Diabetes, Obesity and Metabolism 17:2, pages 188-197.
Crossref
Crossref
Curtis TriplittSusan Cornell. (2015) Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S31526.
Crossref
Crossref
Virginia Valentine & Deborah Hinnen. (2015) Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes 33:1, pages 5-13.
Crossref
Crossref
Kirk Ways, Mark D. Johnson, Rao N. V. S. Mamidi, James Proctor, Sandra De Jonghe & Calvert Louden. (2014) Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity. Toxicologic Pathology 43:1, pages 48-56.
Crossref
Crossref
L. Ji, P. Han, Y. Liu, G. Yang, N. K. Dieu Van, U. Vijapurkar, R. Qiu & G. Meininger. (2015) Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes, Obesity and Metabolism 17:1, pages 23-31.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
R. HoltropR. Holtrop. 2015. De oudere patiënt met diabetes mellitus type 2. De oudere patiënt met diabetes mellitus type 2
75
93
.
David Polidori, Sue Sha, Tim Heise, Jaya Natarajan, Eunice Artis, Shean-Sheng Wang, Nicole Vaccaro, Paul Rothenberg & Alin Stirban. (2015) Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics. Clinical Pharmacology in Drug Development 4:1, pages 12-17.
Crossref
Crossref
Alan Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Cristiana Mayer, Albert Fung, Wayne Shaw, Keith Usiskin, Mehul Desai & Gary Meininger. (2014) Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocrine Disorders 14:1.
Crossref
Crossref
Matthew R. Weir, Andrzej Januszewicz, Richard E. Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung & Gary Meininger. (2014) Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 16:12, pages 875-882.
Crossref
Crossref
W. M. Valencia & H. Florez. (2014) Pharmacological treatment of diabetes in older people. Diabetes, Obesity and Metabolism 16:12, pages 1192-1203.
Crossref
Crossref
B Haas, N Eckstein, V Pfeifer, P Mayer & M D S Hass. (2014) Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition & Diabetes 4:11, pages e143-e143.
Crossref
Crossref
S. Sha, D. Polidori, T. Heise, J. Natarajan, K. Farrell, S.-S. Wang, D. Sica, P. Rothenberg & L. Plum-Mörschel. (2014) Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 16:11, pages 1087-1095.
Crossref
Crossref
Priyanka Malla, Rajnish Kumar, Manoj K. Mahapatra & Manoj Kumar. (2014) Ramping Glucosuria for Management of Type 2 Diabetes Mellitus: An Emerging Cynosure. Medicinal Research Reviews 34:6, pages 1146-1167.
Crossref
Crossref
Bernard Peene & Katrien Benhalima. (2014) Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism 5:5, pages 124-136.
Crossref
Crossref
J.-F. Yale, G. Bakris, B. Cariou, J. Nieto, E. David-Neto, D. Yue, E. Wajs, K. Figueroa, J. Jiang, G. Law, K. Usiskin & G. Meininger. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity and Metabolism 16:10, pages 1016-1027.
Crossref
Crossref
Peter Stein, Jolene K. Berg, Linda Morrow, David Polidori, Eunice Artis, Sarah Rusch, Nicole Vaccaro & Damayanthi Devineni. (2014) Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism 63:10, pages 1296-1303.
Crossref
Crossref
John P.H. Wilding. (2014) The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63:10, pages 1228-1237.
Crossref
Crossref
Xu-Ping Yang, Dan Lai, Xiao-Yan Zhong, Hong-Ping Shen & Yi-Lan Huang. (2014) Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. European Journal of Clinical Pharmacology 70:10, pages 1149-1158.
Crossref
Crossref
Molly Livingston & Jennifer N. Clements. (2014) Canagliflozin. Journal of the American Academy of Physician Assistants 27:9, pages 47-50.
Crossref
Crossref
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch, Sabine Arnolds, Linda Morrow, Heike Spitzer, Keith Demarest & Paul Rothenberg. (2014) Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE 9:8, pages e105638.
Crossref
Crossref
Go Woon Kim & Sung Hyun Chung. (2014) Clinical implication of SGLT2 inhibitors in type 2 diabetes. Archives of Pharmacal Research 37:8, pages 957-966.
Crossref
Crossref
Dainius A. Balis, Cindy Tong & Gary Meininger. (2014) Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5‐anhydroglucitol (坎格列净，一种钠‐葡萄糖共转运体2抑制剂，对血清1,5‐脱水葡萄糖醇测定的影响). Journal of Diabetes 6:4, pages 378-380.
Crossref
Crossref
Rong Qiu, George Capuano & Gary Meininger. (2014) Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. Journal of Clinical & Translational Endocrinology 1:2, pages 54-60.
Crossref
Crossref
Farhad M. Hasan, Mazen Alsahli & John E. Gerich. (2014) SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice 104:3, pages 297-322.
Crossref
Crossref
Lindsey K. Elmore, Sara Baggett, Jeffrey A. Kyle & Jessica W. Skelley. (2014) A Review of the Efficacy and Safety of Canagliflozin in Elderly Patients with Type 2 Diabetes. The Consultant Pharmacist 29:5, pages 335-346.
Crossref
Crossref
T. Forst, R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger & P. Stein. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, Obesity and Metabolism 16:5, pages 467-477.
Crossref
Crossref
M. Monami, C. Nardini & E. Mannucci. (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 16:5, pages 457-466.
Crossref
Crossref
Raymond V. Oliva & George L. Bakris. (2014) Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. Journal of the American Society of Hypertension 8:5, pages 330-339.
Crossref
Crossref
Damayanthi Devineni, Nicole Vaccaro, David Polidori, Sarah Rusch & Ewa Wajs. (2014) Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants. Clinical Therapeutics 36:5, pages 698-710.
Crossref
Crossref
Greg L. Plosker. (2014) Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:7, pages 807-824.
Crossref
Crossref
David Polidori, Andrea Mari & Ele Ferrannini. (2014) Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57:5, pages 891-901.
Crossref
Crossref
William L. Baker, Lindsay R. Smyth, Daniel M. Riche, Emily M. Bourret, Kevin W. Chamberlin & William B. White. (2014) Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. Journal of the American Society of Hypertension 8:4, pages 262-275.e9.
Crossref
Crossref
Harold E. Bays, Richard Weinstein, Gordon Law & William Canovatchel. (2013) Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity 22:4, pages 1042-1049.
Crossref
Crossref
Lucio R. Volino, Eva Y. Pan & Rupal Patel Mansukhani. (2014) Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors in Type 2 Diabetes: A Literature Review of Approved Products. Pharmacology & Pharmacy 05:11, pages 1029-1058.
Crossref
Crossref
Hala Yamout, Vlado Perkovic, Melanie Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger & George Bakris. (2014) Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology 40:1, pages 64-74.
Crossref
Crossref
J. P. H. Wilding, G. Charpentier, P. Hollander, G. González‐Gálvez, C. Mathieu, F. Vercruysse, K. Usiskin, G. Law, S. Black, W. Canovatchel & G. Meininger. (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International Journal of Clinical Practice 67:12, pages 1267-1282.
Crossref
Crossref
Harold Bays. (2013) Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Therapy 4:2, pages 195-220.
Crossref
Crossref
Etie Moghissi. (2013) Management of Type 2 Diabetes Mellitus in Older Patients: Current and Emerging Treatment Options. Diabetes Therapy 4:2, pages 239-256.
Crossref
Crossref
F. J. Lavalle-González, A. Januszewicz, J. Davidson, C. Tong, R. Qiu, W. Canovatchel & G. Meininger. (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:12, pages 2582-2592.
Crossref
Crossref
Stefanie C. Nigro, Daniel M. Riche, Michelle Pheng & William L. Baker. (2013) Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes. Annals of Pharmacotherapy 47:10, pages 1301-1311.
Crossref
Crossref
Pablo J Aschner. (2013) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 3:4, pages 343-350.
Crossref
Crossref